View Filing Data

Statement Of Financial Position Classified - USD ($) $ in Millions	Sep. 30, 2009	Dec. 31, 2008
Current Assets:
Cash and cash equivalents	$ 204.1	$ 297.9
Collateral from securities lending, at fair value	0.0	426.9
Marketable securities, including pledged securities of $50.0 and $283.8	93.7	310.1
Accounts receivable, net of allowance of $2.0 and $1.8	264.0	234.0
Other current assets	119.6	189.1
Cash performance bonds and security deposits	6,824.8	17,653.5
Total current assets	7,506.2	19,111.5
Property, net of accumulated depreciation and amortization of $525.8 and $479.5	726.9	707.2
Intangible assets - trading products	16,982.0	16,982.0
Intangible assets - other, net	3,277.1	3,369.4
Goodwill	7,549.3	7,519.2
Other assets	478.1	469.4
Total Assets	36,519.6	48,158.7
Current Liabilities:
Accounts payable	36.1	71.0
Payable under securities lending agreements	0.0	456.8
Short-term debt	299.7	249.9
Other current liabilities	157.8	211.8
Cash performance bonds and security deposits	6,824.8	17,653.5
Total current liabilities	7,318.4	18,643.0
Long-term debt	2,239.3	2,966.1
Deferred tax liabilities, net	7,669.9	7,728.3
Other liabilities	161.7	132.7
Total Liabilities	17,389.3	29,470.1
Shareholders' Equity:
Additional paid-in capital	17,144.4	17,128.5
Retained earnings	2,113.9	1,719.7
Accumulated other comprehensive income (loss)	(128.7)	(160.3)
Total Shareholders' Equity	19,130.3	18,688.6
Total Liabilities and Shareholders' Equity	36,519.6	48,158.7
Preferred stock
Shareholders' Equity:
Preferred stock	0.0	0.0
Series A junior participating preferred stock
Shareholders' Equity:
Preferred stock	0.0	0.0
Class A common stock
Shareholders' Equity:
Common stock	0.7	0.7
Class B common stock
Shareholders' Equity:
Common stock	$ 0.0	$ 0.0

Statement Of Financial Position Classified (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2009	Dec. 31, 2008
Statement [Line Items]
Marketable securities, pledged securities	$ 50.0	$ 283.8
Accounts receivable, allowance	2.0	1.8
Property, accumulated depreciation and amortization	$ 525.8	$ 479.5
Preferred stock
Statement [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	9,860,000	9,860,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Series A junior participating preferred stock
Statement [Line Items]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	140,000	140,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Class A common stock
Statement [Line Items]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	66,400,000	66,417,000
Common stock, shares outstanding	66,400,000	66,417,000
Class B common stock
Statement [Line Items]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000	3,000
Common stock, shares issued	3,000	3,000
Common stock, shares outstanding	3,000	3,000

Statement Of Income Securities Based Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2009	Sep. 30, 2008	Sep. 30, 2009	Sep. 30, 2008
Revenues
Clearing and transaction fees	$ 540.6	$ 558.7	$ 1,605.2	$ 1,542.3
Quotation data fees	81.4	75.7	249.0	192.3
Processing services	0.1	17.9	0.3	53.9
Access and communication fees	11.4	10.9	34.5	32.2
Other	16.9	17.7	56.3	48.5
Total Revenues	650.4	680.9	1,945.3	1,869.2
Expenses
Compensation and benefits	87.3	84.5	262.0	231.4
Communications	11.5	11.5	35.5	39.1
Technology support services	11.3	11.9	34.7	47.0
Professional fees and outside services	17.9	17.0	61.9	47.8
Amortization of purchased intangibles	30.7	29.1	94.5	63.2
Depreciation and amortization	32.3	34.1	93.4	102.9
Occupancy and building operations	19.1	18.9	57.3	52.9
Licensing and other fee agreements	21.2	19.3	67.5	44.8
Restructuring	0.6	0.1	5.2	2.1
Other	17.1	33.8	46.7	73.7
Total Expenses	249.0	260.2	758.7	704.9
Operating Income	401.4	420.7	1,186.6	1,164.3
Non-Operating Income (Expense)
Investment income	10.5	18.0	22.4	41.4
Impairment of long-term investment	(22.4)	0.0	(22.4)	0.0
Gains (losses) on derivative investments	0.0	7.4	0.0	(7.8)
Securities lending interest income	0.0	8.6	2.8	32.2
Securities lending interest and other costs	0.0	(28.9)	(0.1)	(48.2)
Interest and other borrowing costs	(32.1)	(17.9)	(103.2)	(21.6)
Guarantee of exercise right privileges	0.0	8.0	0.0	12.8
Equity in losses of unconsolidated subsidiaries	(1.6)	(20.0)	(4.5)	(27.9)
Other income (expense)	0.0	0.1	(0.4)	(8.4)
Total Non-Operating Income (Expense)	(45.6)	(24.7)	(105.4)	(27.5)
Income before Income Taxes	355.8	396.0	1,081.2	1,136.8
Income tax provision	153.5	227.3	458.0	483.4
Net Income	$ 202.3	$ 168.7	$ 623.2	$ 653.4
Earnings per Common Share:
Basic	$ 3.05	$ 2.82	$ 9.39	$ 11.66
Diluted	$ 3.04	$ 2.81	$ 9.37	$ 11.61
Weighted Average Number of Common Shares:
Basic	66,384	59,870	66,339	56,054
Diluted	66,573	60,086	66,514	56,302

Statement Of Shareholders Equity And Other Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2009	Sep. 30, 2008	Sep. 30, 2009	Sep. 30, 2008
Accumulated Other Comprehensive Income (Loss)
Beginning Balance			$ 18,688.6	$ 12,305.6
Comprehensive income:
Net income	$ 202.3	$ 168.7	623.2	653.4
Change in net unrealized loss/gain on securities, net of tax of $16.3 in 2009 and $7.7 in 2008			25.2	(10.9)
Change in net actuarial loss on defined benefit plans, net of tax of $0.9 in 2009 and $0.2 in 2008			(1.4)	0.4
Change in net unrealized loss on derivatives, net of tax of $2.8 in 2009 and $0.5 in 2008			4.4	(0.8)
Change in foreign currency translation adjustment, net of tax of $2.2 in 2009 and $4.1 in 2008			3.4	(6.1)
Total comprehensive income			654.8	636.0
Cash dividends on common stock of $3.45 per share in 2009 and $8.45 per share in 2008			(229.0)	(538.4)
Class A common stock issued in exchange for BM&FBovespa SA stock				631.4
Class A common stock issued in NYMEX Holdings merger, including vested stock options, restricted stock units and issuance costs				5,963.3
Tax benefit of stock issuance costs related to CBOT Holdings merger				6.4
Repurchase of Class A common stock			(27.0)	(24.0)
Exercise of stock options			15.2	11.4
Excess tax benefits from option exercises and restricted stock vesting			1.0	7.6
Shares issued to Board of Directors			2.4	2.5
Shares issued under Employee Stock Purchase Plan			0.7	0.7
Stock-based compensation			23.6	26.3
Ending Balance	$ 19,130.3	$ 19,028.8	$ 19,130.3	$ 19,028.8
Class A Common Stock (Shares)
Accumulated Other Comprehensive Income (Loss)
Beginning Balance			66,417,000	53,278,000
Comprehensive income:
Class A common stock issued in exchange for BM&FBovespa SA stock				1,189,000
Class A common stock issued in NYMEX Holdings merger, including vested stock options, restricted stock units and issuance costs				12,566,000
Repurchase of Class A common stock			(139,000)	(62,000)
Exercise of stock options			92,000	106,000
Vesting of issued restricted Class A common stock			16,000	6,000
Shares issued to Board of Directors			12,000	5,000
Shares issued under Employee Stock Purchase Plan			2,000	2,000
Ending Balance	66,400,000	67,090,000	66,400,000	67,090,000
Class B Common Stock (Shares)
Accumulated Other Comprehensive Income (Loss)
Beginning Balance			3,000	3,000
Comprehensive income:
Ending Balance	3,000	3,000	3,000	3,000
Common Stock and Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Beginning Balance			$ 17,129.2	$ 10,689.3
Comprehensive income:
Class A common stock issued in exchange for BM&FBovespa SA stock				631.4
Class A common stock issued in NYMEX Holdings merger, including vested stock options, restricted stock units and issuance costs				5,963.3
Tax benefit of stock issuance costs related to CBOT Holdings merger				6.4
Repurchase of Class A common stock			(27.0)	(24.0)
Exercise of stock options			15.2	11.4
Excess tax benefits from option exercises and restricted stock vesting			1.0	7.6
Shares issued to Board of Directors			2.4	2.5
Shares issued under Employee Stock Purchase Plan			0.7	0.7
Stock-based compensation			23.6	26.3
Ending Balance	$ 17,145.1	$ 17,314.9	17,145.1	17,314.9
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Beginning Balance			1,719.7	1,619.4
Comprehensive income:
Net income			623.2	653.4
Cash dividends on common stock of $3.45 per share in 2009 and $8.45 per share in 2008			(229.0)	(538.4)
Ending Balance	2,113.9	1,734.4	2,113.9	1,734.4
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Beginning Balance			(160.3)	(3.1)
Comprehensive income:
Change in net unrealized loss/gain on securities, net of tax of $16.3 in 2009 and $7.7 in 2008			25.2	(10.9)
Change in net actuarial loss on defined benefit plans, net of tax of $0.9 in 2009 and $0.2 in 2008			(1.4)	0.4
Change in net unrealized loss on derivatives, net of tax of $2.8 in 2009 and $0.5 in 2008			4.4	(0.8)
Change in foreign currency translation adjustment, net of tax of $2.2 in 2009 and $4.1 in 2008			3.4	(6.1)
Ending Balance	$ (128.7)	$ (20.5)	$ (128.7)	$ (20.5)

Statement Of Shareholders Equity And Other Comprehensive Income (Parenthetical) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2009	Sep. 30, 2008
Statement [Line Items]
Change in net unrealized loss/gain on securities, tax	$ 16.3	$ 7.7
Change in net actuarial loss on defined benefit plans, tax	0.9	0.2
Change in net unrealized loss on derivatives, tax	2.8	0.5
Change in foreign currency translation adjustment, tax	$ 2.2	$ 4.1
Cash dividends on common stock, per share	$ 3.45	$ 8.45

Statement Of Cash Flows Indirect Securities Based Operations - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2009	Sep. 30, 2008
Cash Flows from Operating Activities
Net income	$ 623.2	$ 653.4
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	23.6	26.3
Amortization of shares issued to Board of Directors	1.9	1.7
Amortization of purchased intangibles	94.5	63.2
Depreciation and amortization	93.4	102.9
Recognition of in-process research and development acquired from Credit Market Analysis Limited	0.0	3.7
Allowance for doubtful accounts	0.2	0.6
Net accretion of discounts and amortization of premiums on marketable securities	(2.6)	(0.2)
Net accretion of discounts and amortization of debt financing costs	11.6	2.2
Loss on sale of metals trading products	0.0	2.8
Net loss on derivative investments	0.0	7.8
Impairment of securities lending assets	0.0	21.7
Impairment of goodwill and intangible assets	0.0	14.1
Impairment of long-term investment	22.4	0.0
Guarantee of exercise right privileges	0.0	(12.8)
Equity in losses of unconsolidated subsidiaries	4.5	27.9
Deferred income taxes	(28.9)	(32.2)
Change in assets and liabilities:
Accounts receivable	(30.2)	(25.9)
Other current assets	(8.4)	60.1
Other assets	(7.6)	(16.7)
Accounts payable	(34.9)	6.1
Income taxes payable	1.7	22.9
Other current liabilities	(56.2)	(91.3)
Other liabilities	29.6	24.4
Net Cash Provided by Operating Activities	737.8	862.7
Cash Flows from Investing Activities
Proceeds from maturities of available-for-sale marketable securities	389.1	254.1
Purchases of available-for-sale marketable securities	(159.9)	(168.4)
Net change in NYMEX securities lending program investments	425.9	119.3
Purchases of property, net	(112.9)	(119.4)
Acquisition of Credit Market Analysis Limited, net of cash received	0.0	(94.2)
Acquisition of NYMEX Holdings, Inc., net of cash received	0.0	(2,769.9)
NYMEX membership rights payments	0.0	(612.0)
Merger-related transaction costs	0.0	(17.5)
Purchase of derivative related to BM&FBovespa SA investment	0.0	(45.2)
Proceeds from sale of metals trading products	0.0	15.0
Capital contributions to FXMarketSpace Limited	(2.8)	(7.2)
Net Cash Provided by (Used in) Investing Activities	539.4	(3,445.4)
Cash Flows from Financing Activities
Proceeds (repayments) of commercial paper, net	(1,168.8)	1,035.0
Proceeds from other borrowings, net of issuance costs	743.5	2,883.9
Repayment of other borrowings	(250.0)	(1,282.9)
Net change in NYMEX securities lending program liabilities	(456.8)	(119.3)
Cash dividends	(229.0)	(202.7)
Repurchase of Class A common stock, including costs	(27.0)	(14.2)
Proceeds from exercise of stock options	15.2	11.4
Excess tax benefits from option exercises and restricted stock vesting	1.2	7.9
Proceeds from Employee Stock Purchase Plan	0.7	0.7
Net Cash Provided by (Used in) Financing Activities	(1,371.0)	2,319.8
Net change in cash and cash equivalents	(93.8)	(262.9)
Cash and cash equivalents, beginning of period	297.9	845.3
Cash and Cash Equivalents, End of Period	204.1	582.4
Supplemental Disclosure of Cash Flow Information
Income taxes paid	469.6	459.6
Interest paid (excluding securities lending program)	88.2	6.9
Non-cash investing activities:
Change in net unrealized securities gains (losses)	41.5	(18.6)
Change in net unrealized derivatives gains (losses)	7.2	(1.3)
Non-cash financing activities:
Fair value of Class A common stock, stock options and restricted stock units issued in connection with NYMEX Holdings merger	0.0	5,963.3
Fair value of Class A common stock issued in exchange for BM&FBovespa SA stock	0.0	631.4
Dividends declared but unpaid on Class A common stock	$ 0.0	$ 335.7

1. Basis of Presentation	9 Months Ended
1. Basis of Presentation	Sep. 30, 2009
Notes to Financial Statements [Abstract]
1. Basis of Presentation	1. Basis of Presentation CME Group Inc. (CME Group) acquired Credit Market Analysis Limited, a private company incorporated in the United Kingdom, and its three subsidiaries (collectively, CMA) on March 23, 2008. The financial statements and accompanying notes presented in this report include the financial results of CMA beginning on March 24, 2008. On August 22, 2008, CME Group completed its merger with NYMEX Holdings, Inc. (NYMEX Holdings). The financial statements and accompanying notes presented in this report include the financial results of the former NYMEX Holdings and its subsidiaries beginning on August 23, 2008. The accompanying interim consolidated financial statements have been prepared by CME Group without audit. Certain notes and other information normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. The consolidated financial statements consist of CME Group and its subsidiaries (collectively, the company), including Chicago Mercantile Exchange Inc. (CME), Board of Trade of the City of Chicago, Inc. (CBOT), New York Mercantile Exchange, Inc. (NYMEX) and their respective subsidiaries (collectively, the exchange). In the opinion of management, the accompanying consolidated financial statements include all normal recurring adjustments considered necessary to present fairly the financial position of the company at September 30, 2009 and December 31, 2008 and the results of operations and cash flows for the periods indicated. Quarterly results are not necessarily indicative of results for any subsequent period. The accompanying consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto in CME Group’s Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission (SEC) on March 2, 2009.

2. Business Combinations

9 Months Ended

Sep. 30, 2009

Notes to Financial Statements [Abstract]

2. Business Combinations

2. Business Combinations

Effective August 22, 2008, CME Group completed its merger with NYMEX Holdings. The company entered into this merger primarily as a means to expand its product base, further leverage its existing operating model, extend its presence in the over-the-counter market and better position itself to compete on a global scale.

Under purchase accounting, CME Group is considered the acquirer of NYMEX Holdings. The purchase price consists of the following (in millions):


Acquisition of NYMEX Holdings’ outstanding common stock:
In exchange for CME Group’s Class A common stock	$	5,931.2
In exchange for cash		3,412.6
Fair value of NYMEX Holdings’ stock options and restricted stock units assumed		43.7
Merger-related transaction costs		51.8

Total Purchase Price	$	9,439.3

Acquisition of common stock. Pursuant to the merger agreement, NYMEX Holdings’ shareholders elected to receive cash, stock or a combination thereof as consideration for their shares. The aggregate consideration included a mandatory cash component equal to the product of NYMEX Holdings’ common stock outstanding at August 22, 2008 and $36.00 per share. Based on the election for cash and stock as subject to the mandatory cash requirement, CME Group issued 12.5 million shares of Class A common stock to NYMEX Holdings’ shareholders. The share price of $473 used to calculate the fair value of stock issued was based on the average closing price of CME Group’s Class A common stock for the five-day period beginning two trading days before and ending two trading days after March 17, 2008 (the merger announcement date).

Fair value of stock options and restricted stock units assumed. At the close of the merger, NYMEX Holdings had 1,412,000 stock options and 188,700 restricted stock units outstanding. Each stock option and restricted stock unit was converted using an exchange ratio of 0.2378 derived from the allocation of cash and stock consideration to the shareholders in accordance with the merger agreement.

The fair value of the stock options was determined using a share price of $342, the closing price of CME Group’s Class A common stock on August 21, 2008. The fair value of stock options was calculated using a Black-Scholes valuation model with the following assumptions: expected lives of 0.1 to 4.9 years; risk-free interest rates of 1.7% to 3.0%; expected volatility of 45%; and a dividend yield of 1.3%. The portion of the fair value of unvested stock options related to future service was allocated to deferred stock-based compensation and is still being amortized over the remaining vesting period.

Merger-related transaction costs. These include costs incurred by CME Group for investment banking fees, legal and accounting fees, and other external costs directly related to the merger.

Final purchase price allocation. The purchase price has been allocated to NYMEX Holdings’ net tangible and identifiable intangible assets based on their estimated fair values as of August 22, 2008.


(in millions)
Cash and cash equivalents	$	642.7
Other current assets		794.6
Property and equipment		260.6
Intangible assets		10,664.6
Other non-current assets		130.2
Accounts payable and other current liabilities		(726.7	)
Restructuring liabilities		(39.1	)
Membership rights payments		(612.0	)
Long-term deferred tax liabilities, net		(4,026.7	)
Other non-current liabilities		(125.3	)
Deferred stock-based compensation		10.7

Total Tangible and Intangible Assets and Liabilities		6,973.6
Goodwill		2,465.7

Total Purchase Price	$	9,439.3

The excess of the purchase price over the net tangible and identifiable intangible assets was recorded as goodwill. The intangible assets and goodwill acquired are not deductible for tax purposes except for a small portion of goodwill attributable to merger-related transaction costs.

Pre-merger contingencies. The company has not identified any material unrecorded pre-merger contingencies that are both probable and reasonably estimable.

Pro forma results. The following unaudited condensed pro forma consolidated income statements assume that the NYMEX Holdings merger was completed as of January 1, 2007. Pro forma results have been prepared as of the beginning of the year prior to the date of the merger in accordance with SEC guidelines.


(in millions, expect per share data)	Quarter Ended September 30, 2008			Nine Months Ended September 30, 2008
Total Revenues	$	794.4		$	2,383.9
Total Expenses		339.2			925.7
Total Non-Operating Income (Expense)		(55.8	)		(111.4	)
Net Income		168.1			759.3
Earnings per Common Share:
Basic		2.51			11.36
Diluted		2.50			11.32

This pro forma information has been prepared for comparative purposes only and is not intended to be indicative of past or future results. The pro forma information for the periods presented includes purchase accounting effects on historical NYMEX Holdings’ operating results, amortization of purchased intangible assets, stock-based compensation expense for unvested stock options as well as the impact of NYMEX’s membership rights payments on investment income. Results for the quarter and nine months ended September 30, 2008 include NYMEX Holdings’ merger-related transaction costs of approximately $43.6 million and $52.7 million, respectively.

3. Performance Bonds and Security Deposits	9 Months Ended
3. Performance Bonds and Security Deposits	Sep. 30, 2009
Notes to Financial Statements [Abstract]
3. Performance Bonds and Security Deposits	3. Performance Bonds and Security Deposits CME maintains performance bond and security deposit requirements for futures and options traded on or cleared through CME, CBOT, NYMEX or other exchange marketplaces, as well as for over-the-counter (OTC) products listed for clearing only. Each firm that clears futures, options and OTC products is required to deposit acceptable collateral and maintain specified performance bonds and security deposits principally in the form of cash, funds deposited in the various Interest Earning Facility programs, U.S. government and certain foreign government securities, bank letters of credit, shares of specific U.S. equity securities or gold. Clearing firm positions executed in CME, CBOT and NYMEX exchange marketplaces and cleared-only contracts are subject to the guarantee of CME. Each clearing firm’s positions are separately accounted for in regulated and non-regulated accounts, for which performance bond and security deposit requirements are calculated. Performance bonds and security deposits are available to meet the financial obligations of that clearing firm to CME. In the event that performance bonds and security deposits of a defaulting clearing firm are inadequate to fulfill that clearing firm’s outstanding financial obligation, the entire security deposit fund is available to cover potential losses after first utilizing operating funds of CME in excess of amounts needed for normal operations. Cash performance bonds and security deposits may fluctuate due to the investment choices available to clearing firms and the change in the amount of deposit required. As a result, these offsetting liabilities may vary significantly over time. In addition, the rules and regulations of CBOT require certain minimum financial requirements for delivery of physical commodities. To satisfy these requirements, CBOT clearing firms must deposit collateral with CME in the form of cash, U.S. Treasury securities or letters of credit. CME accounts for its guarantee of contract settlement in accordance with current accounting guidance. CME marks to market all open positions at least twice a day and requires payment from clearing firms whose positions have lost value and makes payments to clearing firms whose positions have gained value. Under the extremely unlikely scenario of simultaneous default by every clearing firm who has open positions with unrealized losses, the maximum exposure related to CME’s guarantee would be approximately one half day of changes in fair value of all open positions, before considering CME’s ability to access defaulting firms’ performance bond and security deposit balances as well as other available resources. During the first nine months of 2009, CME transferred an average of approximately $3.1 billion a day through its clearing system for settlement from clearing firms whose positions have lost value to clearing firms whose positions have gained value. CME reduces its guarantee exposure through initial and maintenance performance bond requirements and mandatory security deposits. The company believes that the guarantee liability is immaterial and therefore has not recorded any liability at September 30, 2009.

4. Intangible Assets and Goodwill

9 Months Ended

Sep. 30, 2009

Notes to Financial Statements [Abstract]

4. Intangible Assets and Goodwill

4. Intangible Assets and Goodwill

Intangible assets consisted of the following at September 30, 2009 and December 31, 2008:


	September 30, 2009									December 31, 2008
(in millions)	Cost			Accumulated Amortization			Net Book Value			Cost			Accumulated Amortization			Net Book Value
Amortizable Intangible Assets:
Clearing firm, market data and other customer relationships	$	2,842.5		$	(161.9	)	$	2,680.6		$	2,842.5		$	(90.3	)	$	2,752.2
Lease-related intangibles		83.2			(18.7	)		64.5			83.2			(9.9	)		73.3
Dow Jones licensing agreement		74.0			(14.9	)		59.1			74.0			(9.9	)		64.1
Technology-related intellectual property		28.4			(7.4	)		21.0			28.4			(3.9	)		24.5
Open interest		12.3			(12.3	)		—			12.3			(9.5	)		2.8
Market maker agreement		9.7			(5.5	)		4.2			9.7			(4.3	)		5.4
Other (a)		3.6			(2.3	)		1.3			3.9			(1.8	)		2.1

		3,053.7			(223.0	)		2,830.7			3,054.0			(129.6	)		2,924.4
Foreign currency translation adjustments		(7.1	)		(0.8	)		(7.9	)		(9.4	)		0.3			(9.1	)

Total Amortizable Intangible Assets	$	3,046.6		$	(223.8	)	$	2,822.8		$	3,044.6		$	(129.3	)	$	2,915.3


Indefinite-Lived Intangible Assets:
Trading products							$	16,982.0								$	16,982.0


Trade names		452.1			452.1
Other (b)		2.6			2.6

		17,436.7			17,436.7
Foreign currency translation adjustments		(0.4	)		(0.6	)

Total Indefinite-Lived Intangible Assets		17,436.3			17,436.1

Total Intangible Assets	$	20,259.1		$	20,351.4

(a)	At September 30, 2009, other amortizable intangible assets consist of non-compete and service agreements. At December 31, 2008, other amortizable intangible assets consist primarily of non-compete and service agreements and trade names with limited lives.

(b)	At September 30, 2009, other indefinite-lived intangible assets consist of products in development. At December 31, 2008, other indefinite-lived intangible assets consist of products in development and a regulatory license.

Total amortization expense for intangible assets was $30.7 million and $29.1 million for the quarters ended September 30, 2009 and 2008, respectively. Total amortization expense for intangible assets was $94.5 million and $63.2 million for the nine months ended September 30, 2009 and 2008, respectively. As of September 30, 2009, the future estimated amortization expense related to amortizable intangible assets is expected to be:


(in millions)
Remainder of 2009	$	30.6
2010		121.8
2011		121.6
2012		116.5
2013		110.8
2014		109.2
Thereafter		2,212.3

Goodwill activity consisted of the following for the nine months ended September 30, 2009 and the year ended December 31, 2008:


(in millions)	Balance at December 31, 2008		Acquisitions		Impairment Adjustment			Other Activity (c)			Balance at September 30, 2009
CBOT Holdings	$	5,036.1	$	—	$	—		$	(0.4	)	$	5,035.7
NYMEX Holdings		2,436.7		—		—			26.6			2,463.3
CMA		46.4		—		—			3.9			50.3

Total Goodwill	$	7,519.2	$	—	$	—		$	30.1		$	7,549.3


(in millions)	Balance at January 1, 2008		Acquisitions		Impairment Adjustment			Other Activity (c)			Balance at December 31, 2008
CBOT Holdings	$	5,037.3	$	—	$	—		$	(1.2	)	$	5,036.1
NYMEX Holdings		—		2,438.9		—			(2.2	)		2,436.7
CMA		—		60.6		—			(14.2	)		46.4
Swapstream		11.9		—		(11.9	)		—			—

Total Goodwill	$	5,049.2	$	2,499.5	$	(11.9	)	$	(17.6	)	$	7,519.2

(c)

Other activity consists primarily of adjustments to restructuring costs and tax contingencies for CBOT Holdings and NYMEX Holdings, the recognition of excess tax benefits upon exercise of stock options assumed for CBOT Holdings and NYMEX Holdings, and foreign currency translation adjustments for CMA.

In 2008, the company recorded a $3.2 million and an $11.9 million impairment charge to reduce the carrying amounts of Swapstream intangible assets and goodwill, respectively, to their estimated fair values based on the results of an annual impairment test.

The company conducts goodwill and intangible asset impairment testing at least annually. The company is required to consider a market participant’s perspective when developing the assumptions used to estimate fair value for its impairment tests. It may be possible that the estimated fair value of certain intangible assets and goodwill may be less than net book value when impairment testing is performed in the future. As a result, the company would be required to record an impairment charge at that time.

5. Long-Term Investments	9 Months Ended
5. Long-Term Investments	Sep. 30, 2009
Notes to Financial Statements [Abstract]
5. Long-Term Investments	5. Long-Term Investments As part of its merger with NYMEX Holdings in August 2008, the company acquired an approximately 15% ownership interest in IMAREX ASA (IMAREX). The investment in IMAREX is accounted for as available for sale and is included in other assets in the consolidated balance sheets. At September 30, 2009, the company assessed its investment in IMAREX for other-than-temporary impairment and recognized an impairment charge of $22.4 million due to an extended and significant decline in the market value of IMAREX’s stock. At September 30, 2009, the carrying value of the investment after recognizing impairment was $19.0 million.

6. Debt

9 Months Ended

Sep. 30, 2009

Notes to Financial Statements [Abstract]

6. Debt

6. Debt

Debt consisted of the following:


(in millions)	September 30, 2009		December 31, 2008
Short-term debt:
$250 million floating rate notes due August 2009, interest equal to 3-month LIBOR plus 0.20%, reset quarterly⁽¹⁾	$	—	$	249.9
$300 million floating rate notes due August 2010, interest equal to 3-month LIBOR plus 0.65%, reset quarterly⁽²⁾		299.7		—

Total short-term debt	$	299.7	$	249.9


Long-term debt:
$300 million floating rate notes due August 2010, interest equal to 3-month LIBOR plus 0.65%, reset quarterly⁽²⁾	$	—	$	299.5
Term loan due 2011, interest equal to 3-month LIBOR plus 1%, reset quarterly⁽³⁾		420.5		420.5
$750 million fixed rate notes due August 2013, interest equal to 5.40%		747.9		747.5
$750 million fixed rate notes due February 2014, interest equal to 5.75%		746.0		—
Commercial paper ⁽⁴⁾		324.9		1,498.6

Total long-term debt	$	2,239.3	$	2,966.1

(1)	In October 2008, the company entered into an interest-rate swap agreement that modified the variable interest obligation associated with these notes so that the interest payable on the notes effectively became fixed at a rate of 3.12% beginning with the interest accrued after November 6, 2008.

(2)	In September 2008, the company entered into an interest-rate swap agreement that modified the variable interest obligation associated with these notes so that the interest payable on the notes effectively became fixed at a rate of 3.92% beginning with the interest accrued after November 6, 2008.

(3)	In September 2008, the company entered into an interest-rate swap agreement that modified the variable interest obligation associated with this facility so that the interest payable effectively became fixed at a rate of 4.72% beginning with the interest accrued after October 22, 2008.

(4)

At December 31, 2008, this was the portion of commercial paper backed by the three-year senior credit facility and the 364-day revolving bridge facility. Commercial paper backed by the revolving bridge facility was repaid in February 2009 with the net proceeds from the 5.75% fixed rate notes due February 2014. At September 30, 2009, this represented commercial paper backed by the three-year senior credit facility.

Commercial paper notes with an aggregate par value of $6.0 billion and maturities ranging from 1 to 94 days were issued during the nine months ended September 30, 2009. The weighted average discount rates for commercial paper outstanding at September 30, 2009 and December 31, 2008 were 0.22% and 2.61%, respectively. During the first nine months of 2009 and 2008, the weighted average balance, at par value, of commercial paper outstanding was $677.4 million and $271.0 million, respectively.

Long-term debt maturities, at par value, were as follows as of September 30, 2009:


(in millions)
2011	$	745.5
2012		—
2013		750.0
2014		750.0

Commercial paper is considered to mature in 2011 because it is backed by the three-year senior credit facility, which expires in 2011.

On September 30, 2009, the three-year senior credit facility was amended, at the company’s request, to reduce the aggregate amount of revolving commitments available from $995.0 million to $945.5 million and to reduce the minimum required amount of each request for an increase in revolving commitments from $25.0 million to $10.0 million.

At September 30, 2009, the fair values of the $750.0 million fixed rate notes due 2013 and the $750.0 million fixed rate notes due 2014 were approximately $806.5 million and $822.7 million, respectively. Fair value was estimated using quoted market prices.

7. Restructuring

9 Months Ended

Sep. 30, 2009

Notes to Financial Statements [Abstract]

7. Restructuring

7. Restructuring

CBOT

In August 2007, subsequent to its merger with CBOT Holdings, the company approved and initiated plans to restructure its operations in order to eliminate redundant costs and improve operational efficiencies. Restructuring efforts include reductions in employee positions, the closure of duplicate facilities and consolidation of trading and other technologies. Total estimated restructuring costs of $29.6 million consist primarily of severance and transitional payments and contract termination penalties. Payments for restructuring costs related to the merger with CBOT Holdings were substantially complete by July 2008 from its inception. Through September 30, 2009, the company recorded restructuring expense of $11.2 million under this plan from its inception.

NYMEX

In October 2008, subsequent to its merger with NYMEX Holdings, the company approved and initiated plans to restructure its operations in order to eliminate redundant costs and improve operational efficiencies. Restructuring efforts include reductions in employee positions and consolidation of trading and other technologies.

Total estimated restructuring costs of $47.3 million consist primarily of severance and transitional payments and contract termination payments. Payments for restructuring costs related to the merger with NYMEX Holdings were substantially complete by August 2009. Costs of $39.1 million were recognized as a liability in the allocation of NYMEX Holdings’ purchase price, and accordingly, have resulted in an increase to goodwill. In addition to costs recognized in purchase accounting, costs of $8.2 million have been or are expected to be recognized as restructuring expense over the service period required from transitional employees. Through September 30, 2009, the company recorded restructuring expense of $7.8 million under this plan from its inception.

The following is a summary of restructuring activity (in millions):


	Planned Restructuring Costs		Interest on Deferred Payments		Accrued to Date		Total Cash Payments			Liability at September 30, 2009		Total Expected Payments
Severance and related costs - - CBOT	$	21.2	$	0.1	$	21.3	$	(21.1	)	$	0.2	$	21.4
Severance and related costs - - NYMEX		36.7		—		36.7		(33.9	)		2.8		37.1
Contract terminations - CBOT		7.9		0.3		8.2		(8.2	)		—		8.2
Contract terminations- NYMEX		10.2		—		10.2		(10.2	)		—		10.2

Total Restructuring	$	76.0	$	0.4	$	76.4	$	(73.4	)	$	3.0	$	76.9

Restructuring expense may change as the company executes its approved plans. Future increases in estimates will be recorded as an adjustment to operating expenses. Future decreases in estimates that were recognized as liabilities through the allocation of purchase price will continue to be recorded as adjustments to goodwill.

8. Contingencies	9 Months Ended
8. Contingencies	Sep. 30, 2009
Notes to Financial Statements [Abstract]
8. Contingencies	8. Contingencies Legal Matters. There were two purported class action complaints pending against the former NYMEX Holdings, the former NYMEX Holdings board of directors and CME Group in the Delaware Court of Chancery related to the merger between CME Group and NYMEX Holdings. One of the class actions was brought on behalf of the former NYMEX Holdings’ shareholders and the second class action was brought on behalf of the NYMEX Class A members. On September 30, 2009, the Delaware Court of Chancery granted the defendants’ motions to dismiss the shareholders’ and the NYMEX Class A members’ complaints. The court’s decision remains subject to appeal. On October 14, 2003, the U.S. Futures Exchange, L.L.C. (Eurex U.S.) and U.S. Exchange Holdings, Inc., filed suit against CBOT and CME in the United States District Court for the District of Columbia. The suit alleges that CBOT and CME violated the antitrust laws and tortiously interfered with the business relationship and contract between Eurex U.S. and The Clearing Corporation. Eurex U.S. and U.S. Exchange Holdings, Inc. are seeking a preliminary injunction and treble damages. On December 12, 2003, CBOT and CME filed separate motions to dismiss or, in the event the motion to dismiss is denied, to move the venue to the United States District Court for the Northern District of Illinois. On September 2, 2004, the judge granted CBOT’s and CME’s motions to transfer venue to the Northern District of Illinois. In light of that decision, the judge did not rule on the motions to dismiss. On March 25, 2005, Eurex U.S. filed a second amended complaint in the United States District Court for the Northern District of Illinois. On June 6, 2005, CME and CBOT filed a motion to dismiss the complaint. On August 25, 2005, the judge denied the joint CME/CBOT motion to dismiss. On April 9, 2007, CME and CBOT filed two joint motions for summary judgment. The parties continue to engage in discovery. Based on its investigation to date and advice from legal counsel, the company believes this suit is without merit and intends to defend itself vigorously against these charges. On August 19, 2008, Fifth Market filed a complaint against CME Group and CME seeking a permanent injunction against CME’s Globex system and enhanced damages for what the plaintiff alleges is willful infringement, in addition to costs, expenses and attorneys’ fees. The suit alleges that CME infringes two U.S. patents. Based on its investigation to date and advice from legal counsel, the company believes this suit is without merit and intends to defend itself vigorously against these charges. In addition, the company is a defendant in, and has potential for, various other legal proceedings arising from its regular business activities. While the ultimate results of such proceedings against the company cannot be predicted with certainty, the company believes that the resolution of any of these matters will not have a material adverse effect on its consolidated financial position or results of operations. Employment Agreements. On August 5, 2009, the compensation committee and the board of directors of CME Group approved a revised employment agreement for Craig S. Donohue, the company’s Chief Executive Officer. In the event of a termination under certain circumstances, Mr. Donohue is entitled to a one-time lump sum severance payment equal to two times the sum of his then current base salary plus the amount of his threshold bonus (75% of his current base salary) under the company’s annual bonus incentive plan for that year. Under the terms of his agreement, Mr. Donohue will be entitled to receive a minimum annual base salary of $0.9 million for 2009 and of $1.0 million thereafter during the term of the agreement. This agreement expires on December 31, 2012, unless terminated sooner by the company or Mr. Donohue.

9. Guarantees	9 Months Ended
9. Guarantees	Sep. 30, 2009
Notes to Financial Statements [Abstract]
9. Guarantees	9. Guarantees Guarantee of Exercise Rights Privileges. On August 23, 2006, CBOT Holdings and CBOT, along with a class consisting of certain CBOT full members, filed a lawsuit in the Court of Chancery of the State of Delaware against the Chicago Board Options Exchange, Inc. (CBOE). The lawsuit seeks to enforce and protect the exercise right privileges (ERP). The lawsuit alleges that these ERPs allow CBOT’s full members who hold them to become full members of CBOE and to participate on an equal basis with other members of CBOE in CBOE’s announced plans to demutualize. In July 2009, the court issued its final order approving the terms of the settlement. Pursuant to the terms of the settlement, holders of ERPs could submit a claim to participate in the settlement as a Class A or Class B settlement participant until October 14, 2008. Participating Class A members will share in an equity pool equal to 18% of the total common stock issued by CBOE in its demutualization and will share in a cash pool of up to $300.0 million, subject to a cap of $600,000 per individual. Participating Class B members would be paid $250,000 per ERP. The settlement is in the process of being appealed. In connection with the CBOT Holdings merger, the company provided holders of ERPs the option of tendering their ERP to the company for $250,000 payable following the closing of the merger or to participate in the CBOE lawsuit with a guaranteed payment of up to $250,000 from the company if the lawsuit results in a recovery of less than that amount. The maximum possible aggregate payment under the company’s guarantee, assuming that all outstanding ERPs are paid $250,000 by the company, is $293.0 million. The liability under the guarantee, which is recorded at fair value in other liabilities in the consolidated balance sheets, was estimated at $1.2 million at September 30, 2009. Mutual Offset Agreement. CME and Singapore Exchange Limited (SGX) have a mutual offset agreement. The original term of the renewed agreement was through October 2009. The term of the agreement will be successively renewed for one-year periods unless terminated in advance by either party. Pursuant to such renewals, the current term is through October 2010. Under this agreement, CME can maintain collateral in the form of U.S. Treasury securities or irrevocable letters of credit. At September 30, 2009, CME was contingently liable to SGX on irrevocable letters of credit totaling $33.0 million and had pledged securities with a fair value of $50.0 million. Regardless of the collateral, CME guarantees all cleared transactions submitted through SGX and would initiate procedures designed to satisfy these financial obligations in the event of a default, such as the use of performance bonds and security deposits of the defaulting clearing firm.

10. Stock-Based Payments	9 Months Ended
10. Stock-Based Payments	Sep. 30, 2009
Notes to Financial Statements [Abstract]
10. Stock-Based Payments	10. Stock-Based Payments Total expense for stock-based payments, including shares issued to the board of directors, converted CBOT Holdings options and converted NYMEX Holdings options, was $25.5 million and $28.0 million for the nine months ended September 30, 2009 and 2008, respectively. The total income tax benefit recognized in the consolidated statements of income for stock-based payment arrangements was $10.2 million and $11.3 million for the nine months ended September 30, 2009 and 2008, respectively. In the first nine months of 2009, the company granted employees stock options totaling 173,040 shares under the CME Group Omnibus Stock Plan. The options have a ten-year term with an exercise price ranging from $195 to $332 per share, the closing market prices on the dates of grant. The fair value of these options totaled $20.2 million, measured at the grant dates using the Black-Scholes valuation model, which is recognized as compensation expense on an accelerated basis over the vesting period. The Black-Scholes fair value of the option grant was calculated using the following assumptions: dividend yield ranging from 1.4% to 2.4%; expected volatility ranging from 47% to 49%; risk-free interest rate ranging from 2.4% to 3.2% and expected life ranging from 6.2 to 6.5 years. The grant date weighted average fair value of options granted during the first nine months of 2009 was $117 per share. In the first nine months of 2009, the company also granted 81,629 shares of restricted Class A common stock which generally have a vesting period of two to five years. The fair value of these grants was $23.2 million, which is recognized as compensation expense on an accelerated basis over the vesting period.

11. Fair Value Measurements

9 Months Ended

Sep. 30, 2009

Notes to Financial Statements [Abstract]

11. Fair Value Measurements

11. Fair Value Measurements

Accounting guidance on fair value measurements and related disclosures provides direction for using fair value to measure assets and liabilities by defining fair value and establishing a framework for measuring fair value. The guidance creates a three-level hierarchy that establishes classification of fair value measurements for disclosure purposes.

•

Level 1 inputs, which are considered the most reliable evidence of fair value, consist of quoted prices (unadjusted) for identical assets or liabilities in active markets.

•

Level 2 inputs consist of observable market data, other than Level 1 inputs, such as quoted prices for similar assets and liabilities in active markets or inputs other than quoted prices that are directly observable.

•

Level 3 inputs consist of unobservable inputs which are derived and cannot be corroborated by market data or other entity-specific inputs.

In general, the company uses quoted prices in active markets for identical assets to determine the fair value of marketable securities, securities lending collateral and equity investments. Level 1 assets generally include U.S. Treasury securities, exchange-traded mutual funds, and publicly-traded equity securities. If quoted prices are not available to determine fair value, the company uses other inputs that are observable either directly or indirectly. Assets included in Level 2 consist primarily of U.S. Government agency securities, corporate bonds, municipal bonds, asset-backed securities and certain corporate bonds. Level 3 assets generally include certain corporate bonds and asset-backed securities. These assets have been valued using valuation models with inputs that are both observable and unobservable. The unobservable inputs used in these models are significant to the fair value of the assets and require management’s judgment.

The company determined the fair value of its interest rate swap contracts, considered Level 2 assets, using standard valuation models with market-based observable inputs including forward and spot exchange rates and interest rate curves.

The fair value of the liability for the guarantee of ERPs is derived using probability-weighted Black-Scholes option values for various scenarios. The liability is included in Level 3 because management uses significant unobservable inputs including probability, expected return and volatility factors to determine the fair value.

Financial assets and liabilities recorded in the consolidated balance sheet as of September 30, 2009 are classified in their entirety based on the lowest level of input that is significant to each asset or liability’s fair value measurement.

Financial Instruments Measured at Fair Value on a Recurring Basis:


(in millions)	Level 1		Level 2		Level 3		Total
Assets at Fair Value:
Marketable securities:
U.S. Treasury securities	$	55.1	$	—	$	—	$	55.1
Mutual funds		22.5		—		—		22.5
Corporate bonds		—		0.1		—		0.1
Municipal bonds		—		5.0		—		5.0
Asset-backed securities		—		4.0		—		4.0
U.S. Government agency securities		—		7.0		—		7.0

Total		77.6		16.1		—		93.7
Equity investments		65.5		—		—		65.5

Total Assets at Fair Value	$	143.1	$	16.1	$	—	$	159.2

Liabilities at Fair Value:
Interest rate swap contracts	$	—	$	30.9	$	—	$	30.9
Guarantee of CBOE exercise right privileges		—		—		1.2		1.2

Total Liabilities at Fair Value	$	—	$	30.9	$	1.2	$	32.1

The following is a reconciliation of assets and liabilities at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2009.


(in millions)	Asset- Backed Security ⁽¹⁾			Guarantee of CBOE ERP Liability
Fair value of asset (liability) at January 1, 2009	$	1.5		$	(1.2	)
Realized and unrealized gains (losses):
Included in non-operating income (expense)		1.0			—
Settlements		(2.5	)		—

Fair value of asset (liability) at September 30, 2009	$	—		$	(1.2	)

Total unrealized gains (losses) related to financial assets and liabilities in the consolidated balance sheet at September 30, 2009	$	—		$	—

(1)	This asset-backed security was transferred from the securities lending program investment portfolio to the marketable securities portfolio during June 2009.

During the first nine months of 2009, CME Group did not record impairment on any assets or liabilities that are recorded at fair value on a nonrecurring basis.

12. Earnings Per Common Share

9 Months Ended

Sep. 30, 2009

Notes to Financial Statements [Abstract]

12. Earnings Per Common Share

12. Earnings Per Common Share

Basic earnings per common share is computed by dividing net income by the weighted average number of shares of all classes of common stock outstanding for each reporting period. Diluted earnings per common share reflects the increase in shares using the treasury stock method to reflect the impact of an equivalent number of shares of common stock if stock options were exercised and restricted stock awards were converted into common stock. Outstanding stock options and restricted stock awards of approximately 613,000 and 750,000 were anti-dilutive for the quarter and nine months ended September 30, 2009, respectively. Outstanding stock options of approximately 525,000 and 395,000 were anti-dilutive for the quarter and nine months ended September 30, 2008, respectively. There were no anti-dilutive restricted stock awards for the quarter and nine months ended September 30, 2008. These anti-dilutive shares were not included in the diluted earnings per common share calculations.

Beginning January 1, 2009, a change in accounting guidance requires the use of a two-class method to determine the impact of outstanding stock options and restricted stock awards on diluted earnings per common share. The company determined that the impact of using the two-class method is immaterial. If the impact becomes material, the company will change its application of the guidance.


	Quarter Ended September 30,				Nine Months Ended September 30,
	2009		2008		2009		2008
Net Income (in millions)	$	202.3	$	168.7	$	623.2	$	653.4

Weighted Average Number of Common Shares (in thousands):
Basic		66,384		59,870		66,339		56,054
Effect of stock options		163		208		150		240
Effect of restricted stock awards		26		8		25		8

Diluted		66,573		60,086		66,514		56,302


Earnings per Common Share:
Basic	$	3.05	$	2.82	$	9.39	$	11.66
Diluted		3.04		2.81		9.37		11.61

13. Subsequent Events	9 Months Ended
13. Subsequent Events	Sep. 30, 2009
Notes to Financial Statements [Abstract]
13. Subsequent Events	13. Subsequent Events The company has evaluated subsequent events through November 6, 2009, the date the financial statements were issued, and has determined that there are no subsequent events that require disclosure other than the following event: On October 9, 2009, CME amended its 364-day revolving line of credit, which may be used by its clearing house in certain situations. The amended credit agreement extends the termination date from October 9, 2009 to December 9, 2009.

Document Information	9 Months Ended
Document Information	Sep. 30, 2009
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2009

Entity Information - shares	9 Months Ended
Entity Information - shares	Sep. 30, 2009	Oct. 21, 2009
Trading Symbol	CME
Entity Registrant Name	CME GROUP INC.
Entity Central Index Key	0001156375
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		66,519,078

Label	Element	Value
Class B common stock, Class B-3
Entity Common Stock, Shares Outstanding	dei_EntityCommonStockSharesOutstanding	1,287
Class B common stock, Class B-1
Entity Common Stock, Shares Outstanding	dei_EntityCommonStockSharesOutstanding	625
Class B common stock, Class B-4
Entity Common Stock, Shares Outstanding	dei_EntityCommonStockSharesOutstanding	413
Class B common stock, Class B-2
Entity Common Stock, Shares Outstanding	dei_EntityCommonStockSharesOutstanding	813